It’s been more than six weeks since Zantac and generic formulas of ranitidine were pulled from pharmacy shelves due to carcinogenic impurities, but physicians in Pittsburgh aren’t convinced the recalls are over.
The past year has seen a whole lot of change for the field of cardiology, but it’s hard to discern where that leaves us as we prepare for 2020. MedAxiom President Jerry Blackwell, MD, MBA, helped clarify the situation.
Research out of Brigham and Women’s Hospital in Boston found heart failure patients who self-identify as black, Latinx or female are less likely to be admitted to the hospital’s cardiology department, suggesting admission bias might be a partial contributor to known racial disparities in HF outcomes.
Most patients on DOACs supplement their regimen with over-the-counter products, and one-third take at least one additional product that directly interferes with their blood thinners, according to work published in the Journal of the American Geriatrics Society.
Metformin use is linked to a lower risk of hospitalization for heart failure in patients with type 2 diabetes, a paper in the Journal of the American Heart Association confirms.
Medicine is, and has been for years now, trending toward a more value-based payment system. But what exactly does that mean, and where does cardiology fit in?
California-based tech company HeartVista announced Oct. 29 it had received FDA clearance for its AI-assisted One Click cardiac MRI acquisition software.
